

Advances in Integrated Radionuclide Diagnosis and Therapy for Gastric Cancer: Targets, Tracers and Translational Applications

Yulin Liu^{1,2,3}, Yilin Xiao^{1,2,3}, Yuxing Chen^{1,2,3}, Enqing Meng^{1,2,3}, Min Jin^{1,2,3}, Mengjiao Wu^{1,2,3}, Yan Zong^{1,2,3*} and Hongli Liu^{1,2,3*}

¹Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

²Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China

³Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

*Corresponding author:

Yan Zong and Hongli Liu,
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, China and Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Received: 01 Feb 2026

Accepted: 16 Feb 2026

Published: 19 Feb 2026

J Short Name: CTMCCR

Copyright:

©2026 Yan Zong and Hongli Liu. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and build upon your work non-commercially

Keywords:

Gastric Cancer (GC); Radionuclide; Molecular Imaging; Targeted Radionuclide Therapy (TRT); Radiopharmaceuticals

Citation:

Yan Zong and Hongli Liu, Advances in Integrated Radionuclide Diagnosis and Therapy for Gastric Cancer: Targets, Tracers and Translational Applications. World Journal of Gastro Hep Endo[®] 2026; V31(1): 1-16

1. Abstract

Gastric cancer (GC) remains one of the leading causes of cancer-related deaths worldwide. Although standard treatments including surgery, chemotherapy and immunotherapy have improved patient prognosis, the management of advanced disease and occult metastases continues to present a significant clinical challenge. The integration of nuclear medicine diagnostics and therapy represents a precision medicine model that combines molecular imaging with targeted radionuclide therapy (TRT), emerging as a promising strategy to overcome these limitations. TRT achieves precise delivery of radionuclides to lesions while avoiding non-targeted deposition by conjugating radionuclides with targeted carriers such as small molecules, peptides, or monoclonal antibodies. This approach enhances the efficiency and biological safety of tumor diagnosis and treatment. This review comprehensively summarizes the current status of nuclear medicine diagnostics for gastric cancer, detailing the evolution from metabolic imaging to novel targeted therapies targeting HER2, CLDN18.2, and fibroblast activation protein (FAP). Additionally, we conducted an in-depth analysis of the therapeutic potential of various radionuclides, explored synergistic combination therapy strategies, and outlined obstacles encountered during clinical translation—such as dosimetry and supply chain management—aiming to accelerate the application of these novel therapies in gastric cancer treatment.

2. Introduction

Gastric cancer (GC), as a common gastrointestinal cancer, ranks fifth among all tumours in terms of incidence and fourth in mortality worldwide [1]. It is reported that nearly one million new cases of GC are diagnosed annually globally, with over 650,000 deaths [2]. Major risk factors for GC include *H. pylori* infection, dietary habits, obesity, smoking, and genetic predisposition. Although endoscopy and contrast-enhanced CT remain the gold standard for diagnosis, their sensitivity is limited in detecting occult peritoneal metastases and micro metastatic lesions, which are crucial for accurate staging.

Positron Emission Computed Tomography/Computed Tomography (PET/CT), particularly when using 18F-FDG and FAPI imaging, enhances the accuracy of gastric cancer staging. However, its clinical utility is often compromised by physiological gastric uptake and the low glycolytic activity observed in certain histological subtypes, such as signet ring cell carcinoma and mucinous adenocarcinoma [3, 4].

In terms of treatment, the standard approach for advanced gastric cancer remains a combination of surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. However, treatment often faces challenges due to systemic toxicity, drug resistance, and the influence of the “cold” immune microenvironment commonly found in gastric tumours [5, 6]. Currently, radioisotope-based integrated diagnosis and therapy offers a

transformative approach. In 1941, ¹³¹I was first employed in the treatment of thyroid cancer, marking the beginning of research into radionuclide therapy (RNT) [7]. In recent years, this field has evolved from simple radioactive iodine therapy to complex targeted radionuclide therapy (TRT). TRT utilizes specific carriers—such as peptides, monoclonal antibodies (mAbs), or nanoparticles (NPs)—to deliver cytotoxic radionuclides (e.g., ¹⁷⁷Lu, ²²⁵Ac) [8-10]. Directly to tumour cells [11-14]. This review explores recent advances in the field of integrated diagnosis and treatment for gastric cancer, focusing on emerging molecular targets and the strategic selection of radionuclides to improve patient prognosis.

3. Radionuclide-based Molecular Imaging of Gastric cancer

3.1. Molecular Imaging Limitations of ¹⁸F-FDG and the Cell Proliferation Marker ¹⁸F-FLT

Anaerobic glycolysis refers to the phenomenon where cancer cells rapidly supply energy to the body through glycolysis rather than relying on oxidative phosphorylation for energy production under aerobic conditions, and is considered a key characteristic of cancer [15]. Based on this feature, fluorodeoxyglucose (FDG), as a glucose analog, is widely used in the diagnosis, staging, and preoperative assessment of GC. However, although ¹⁸F-FDG exploits the “Warburg effect” of anaerobic glycolysis, its sensitivity for non-intestinal-type gastric cancer and peritoneal metastases is suboptimal [3, 16]. Meanwhile, approximately 20–30% of gastric cancers (such as early-stage gastric cancer, signet ring cell carcinoma, and mucinous adenocarcinoma) may yield false-negative results due to insufficient ¹⁸F-FDG uptake caused by low glycolytic activity [3, 17]. Additionally, benign lesions such as gastritis, leiomyomas, and polyps may yield false-positive results due to physiological uptake of ¹⁸F-FDG [4].

To solve this problem, researchers investigated the cell proliferation marker ¹⁸F-FLT. ¹⁸F-FLT is internalized and retained within cells via nucleoside transport, accumulating in proliferating tissues and malignant tumors, and is thus regarded as an indicator of tumour proliferation [18]. Herrmann et al. [19], demonstrated through their research that compared to ¹⁸F-FDG, ¹⁸F-FLT exhibits higher sensitivity in detecting locally advanced lesions, histological subtypes such as signet ring cell carcinoma, and regional lymph node metastases, and can be utilized for quantitative analysis [19]. This is primarily due to its lack of physiological uptake in the gastric wall. Staniuk et al. compared ¹⁸F-FLT PET with standard CECT in GC diagnosis, demonstrating for the first time the high sensitivity of ¹⁸F-FLT in identifying regional lymph node metastasis and distant metastasis in GC [20]. Using ROC curve, the sensitivity and specificity of FLT-PET/CT in metastatic regional lymph node assessment were higher than those of CECT. Therefore, ¹⁸F-FLT can effectively compensate for the detection limitations of ¹⁸F-FDG, enabling visualization analysis and efficacy assessment in gastric cancer [21, 22]. Notably, Honma et al. were the first to demonstrate that ¹⁸F-FLT

exhibits extremely high sensitivity in identifying peritoneal dissemination [23]. Peritoneal dissemination is a common pattern of metastasis in gastric cancer recurrence, but its accumulation in the liver limits the assessment of liver metastases.

3.2. Tumor Microenvironment Imaging: FAPI and Hypoxia

The tumor microenvironment (TME) offers novel imaging targets, and molecular imaging techniques for gastric cancer have been further optimized. This advancement partially addresses the limitations of existing molecular diagnostic technologies, thereby enhancing the precision of gastric cancer diagnosis.

As a key component of the tumor microenvironment (TME), cancer-associated fibroblasts (CAFs) play a crucial role in the initiation and progression of cancer [24]. Fibroblast Activation Protein (FAP) serves as a specific marker for cancer-associated fibroblasts (CAFs), exhibiting high expression in various epithelial cancers. It is closely associated with tumor proliferation and progression [25, 26]. Based on the characteristics of FAPI, Researchers have developed a radiotracer based on FAPI (FAP inhibitor, which can specifically target and bind to FAP) for imaging various tumors [27]. Unlike ¹⁸F-FDG, FAPI visualizes tumors by highlighting CAFs within the tumor stroma and extracellular fibrosis [28]. Research has found that 50% of GC cases exhibit strong FAP expression [29]. Although gastric cancer exhibits lower uptake in FAPI PET compared to other gastrointestinal tumors, the relatively high tumor-to-background ratio in FAPI PET—due to the low physiological uptake of the gastric wall—enhances imaging performance. Consequently, FAPI PET holds considerable application potential for gastric cancer diagnosis [30]. Studies indicate that the metabolic parameters of ⁶⁸Ga-FAPI were higher than those of ¹⁸F-FDG in the primary gastric cancer site, lymph nodes, and distant metastases., particularly small metastatic foci in the peritoneum, abdominal lymph nodes, liver, and bones [9,31-34]. Additionally, ⁶⁸Ga-FAPI demonstrates superior imaging performance compared to ¹⁸F-FDG PET in subtypes such as signet ring cell carcinoma [35]. It is evident that compared to ¹⁸F-FDG, ⁶⁸Ga-FAPI is more advantageous for the auxiliary diagnosis and staging of gastric cancer, and can be used to evaluate treatment response and prognosis [36-43].

Tissue hypoxia is a common pathological state in cancer characterized by reduced oxygen supply. Leveraging this feature of cancer, researchers have developed multiple hypoxia PET probes [44, 45]. The first and most widely used radiolabeled hypoxia PET tracer in clinical practice is ¹⁸F-FMISO [46]. However, ¹⁸F-FMISO exhibits slow specific accumulation in tumors and high radioactive concentrations in the gastrointestinal tract, significantly limiting its clinical application. Currently, the primary next-generation hypoxia imaging PET agents include ¹⁸F-FAZA [47], ¹⁸F-FETNIM [48], ¹⁸F-FETA [49], ¹⁸F-HX4 [50] and ¹⁸F-EF5 [51]. Nario et al. [52], developed a novel radiotracer named ¹⁸F-FBNA, and found that compared to the aforementioned tracers, ¹⁸F-FBNA exhibits greater lipophilicity and is more readily captured by GC cells under hypoxic

conditions, resulting in higher cellular uptake [52]. In addition, researchers have identified ^{64}Cu -ATSM [53, 54]. They found that ^{64}Cu -ATSM exhibits greater lipophilicity than ^{18}F -FBNA and has been evaluated in multiple clinical trials. Furthermore, ^{64}Cu -ATSM also accumulates in tumors based on cellular redox potential and reactive oxygen species (ROS) types, making it an indirect biomarker for hypoxic PET imaging [55]. Additionally, researchers have developed a ^{64}Cu -ES PET agent, which has been validated to demonstrate superior therapeutic efficacy compared to other drugs such as ^{64}Cu -ATSM, making it a highly promising therapeutic and diagnostic agent for tumor treatment [56].

In summary, based on the metabolic and proliferative characteristics of GC cells, molecular imaging techniques for GC continue to be optimized and are expected to be further adopted in clinical practice, providing more accurate diagnostic tools for GC.

3.3. Novel Targeted Molecular Probes (Immune PET)

Currently, the detection of most GC target molecules primarily relies on techniques such as immunohistochemistry (IHC), which often present numerous limitations [57]. This procedure is often invasive, causing bodily damage while also potentially leading to cancer metastasis. More importantly, a single *ex vivo* sample may fail to reflect systemic expression patterns or the true status of target molecules within tumor tissue [57, 58]. Radioisotope labeling of GC target molecules combined with PET imaging has emerged as a novel diagnostic approach, demonstrating significant potential for non-invasive imaging and molecular expression detection.

HER2 is a transmembrane tyrosine kinase receptor belonging to the epidermal growth factor receptor (EGFR) family, and its overexpression is relatively common in GC [59]. As an anti-HER2 antibody, trastuzumab (TRZ) has been widely used in the targeted therapy of GC [60]. Guo et al. [60]. Constructed a ^{64}Cu -NOTA-trastuzumab probe by radiolabeling trastuzumab with ^{64}Cu for the specific detection of HER2 overexpression in GC patients [61]. Experimental results demonstrated that ^{64}Cu -NOTA-trastuzumab can detect primary GC lesions and liver metastases, exhibiting superior detection capability and stability compared to ^{18}F -FDG [61]. Reports have also evaluated ^{89}Zr -labeled trastuzumab [62], for the first time in esophagogastric adenocarcinoma (EGA). The study revealed that the ^{89}Zr -trastuzumab probe exhibits specificity for HER2+ EGA and demonstrates high contrast in visualizing both primary tumors and metastases [62]. Similarly, Zhou et al. developed ^{68}Ga -NOTA-MAL-MZHER2 for PET imaging of advanced GC [63]. They found that ^{68}Ga -NOTA-MAL-MZHER2 can detect HER2 expression in GC patients at low doses during early-stage screening. Experimental findings indicate that GC patients exhibiting high affinity for the ^{68}Ga -HER2 affibody demonstrate significantly longer progression-free survival (PFS) compared to those with low affinity (4–9 months vs 2–3 months) [63]. In recent years, numerous PET imaging studies utilizing radionuclide-labeled HER2 have emerged, fully demonstrating the im-

mense potential of HER2-targeted probes [64–67].

As a highly specific tight junction protein exclusively present in gastric epithelial cells, CLDN18.2 exhibits strong positive expression in GC and becomes exposed during malignant progression. It is widely recognized as a potent therapeutic target for GC [68–70]. Hu et al. [71]. Constructed three anti-CLDN18.2 nano-recombinant antibodies and labeled them with ^{89}Zr [71]. They found that two types of ^{89}Zr -anti-CLDN18.2 antibodies (^{89}Zr -anti-CLDN18.2 VHH-ABD and ^{89}Zr -anti-CLDN18.2 VHH-Fc) can be stably and efficiently expressed for tumor uptake and liver accumulation, enabling dynamic monitoring, and quantitative analysis of CLDN18.2 expression in tumors and normal organs [71]. In subsequent clinical studies, researchers found that ^{89}Zr -anti-CLDN18.2 VHH-Fc demonstrated greater specificity and persistence compared to ^{89}Zr -anti-CLDN18.2 VHH-ABD [72]. In addition, Chen et al. constructed ^{89}Zr -DFO-TST001 by radiolabeling the monoclonal antibody TST001 against CLDN18.2 with ^{89}Zr [73]. They found that ^{89}Zr -DFO-TST001 demonstrated excellent specificity and high tumor accumulation at the cellular level [73]. And Wang et al. [74], further validated the excellent *in vivo* tracking capability of the radionuclide-labeled diagnostic PET probe for CLDN18.2+ GC in both mice and humans using the 124I-18B10 probe (TST001, derived from the humanized mouse-derived hybridoma antibody 18B10) [74]. Notably, 124I-18B10 successfully demonstrated the systemic distribution of CLDN18.2 protein in GC patients [74]. Meanwhile, several immuno-PET imaging tracers targeting CLDN18.2 have been demonstrated to be viable for PET imaging, such as immune tracers labeled with $^{68}\text{Ga}/^{64}\text{Cu}/^{18}\text{F}$ that target humanized nanobodies against CLDN18.2 [75, 76]. In addition, Zeng et al. [77]. Comprehensively evaluated the capabilities of the therapeutic radionuclide ^{177}Lu radiolabeled and DOTA-conjugated TST001 in terms of cellular uptake, SPECT imaging, and biodistribution [77]. Results demonstrated that ^{177}Lu -DOTA-TST001 exhibited specific and high tumor uptake in CLDN18.2+ GC mouse models. Furthermore, the study revealed enhanced tumor volume control, more pronounced tumor tissue destruction, stronger cell proliferation inhibition, and low biological toxicity and low biological toxicity for ^{177}Lu -DOTA-TST001, suggesting strong potential for clinical translation [77].

Tropomyosin-2 (Trop2) is a cell surface glycoprotein naturally present in normal cells exhibiting stem cell-like properties [78]. However, its expression is significantly elevated in various cancers, including GC, and is strongly associated with lymph node metastasis and poor prognosis [79–81]. Reports indicate that two nanobodies developed against Trop2 were labeled with ^{68}Ga , yielding ^{68}Ga -NOTA-RTD98 and ^{68}Ga -NOTA-RTD01. The specificity of these probes for solid tumor immune PET imaging was validated [82]. Huang et al. pioneered the use of Trodelvy, an ^{89}Zr -labeled antibody-drug conjugate (ADC) targeting Trop2, to conduct immune PET imaging studies of Trop2 expression in gastric and breast cancer model [83]. Results indicate that ^{89}Zr -DFO-Trodelvy clearly delineates tumor morphol-

ogy, with tumor uptake increasing over time. They concluded that ⁸⁹Zr-DFO-Trodelyv exhibits specific, rapid, and sustained accumulation in tumors with high Trop2 expression, enabling non-invasive monitoring of Trop2 status [83].

Human hepatocyte growth factor receptor (c-MET) is a transmembrane tyrosine kinase normally expressed in epithelial cells [84]. c-MET can induce tumor proliferation and metastasis by activating the MAPK/PI3K pathway [85]. In GC, c-MET is overexpressed and is closely associated with tumor staging and poor prognosis [86]. Earlier studies reported that DN30, an anti-Met monoclonal antibody radiolabeled with ⁸⁹Zr and ¹²⁴I, enabled precise imaging of tumor-targeted tissues, suggesting the potential for physiological monitoring through radionuclide labeling of c-MET [87]. Hepatocyte growth factor (HGF) is the sole physiological activating ligand for c-MET [84]. Price et al. radiolabeled the c-MET-binding antibody AMG102 with ⁸⁹Zr and validated the selective accumulation of ⁸⁹Zr-DFO-AMG102 in tumor tissues with elevated local HGF protein levels in GC models, thereby indirectly reflecting c-MET expression levels [88]. Additionally, Klingler et al. constructed ⁸⁹Zr-DFO-Onartuzumab by labeling Onartuzumab (an anti-human c-MET monoclonal antibody) with ⁸⁹Zr [89]. Immune-PET imaging revealed that ⁸⁹Zr-DFO-Onartuzumab exhibited prolonged circulation time and specific tumor uptake in GC models, confirming its efficacy as a radioligand for the c-MET receptor in GC [89].

Among GCs, there is another relatively rare category of tumors-neuroendocrine tumors (NETs). NETs often exhibit high somatostatin receptor (SSR) expression. Traditionally, SPECT imaging using ¹¹¹In-labeled octreotide analogues has been employed to detect SSR-positive tumors. In recent years, PET-targeted probes utilizing ⁶⁸Ga-labeled SSR analogues (such as ⁶⁸Ga-DOTA-TATE) have significantly enhanced imaging sensitivity for NETs [90]. Concurrently, studies have demonstrated that ⁶⁸Ga-DOTA-TATE offers diagnostic advantages in detecting liver and distant metastases of NETs [91]. Among patients with NET liver metastases, the positive rate in initial pathology reports was 91.4%, while SSR-PET/CT achieved a positive predictive value of 95.5% for detecting NET liver metastases [91]. Furthermore, Ohlendorf et al. validated the diagnostic value of ⁶⁸Ga-DOTA-TATE in NETs through its application in staging assessments and monitoring treatment responses in NET patients [92]. In summary, the ⁶⁸Ga-labeled SSR-targeted tracer demonstrates distinct advantages for the qualitative diagnosis, clinical staging, pathological grading, and efficacy assessment of G1,

G2, and certain G3 NETs, positioning it as a promising targeted probe [92-94].

In addition to the above targets that have been relatively well-studied, numerous potential targets remain unexplored in GC therapy (Table. 1). For example, ⁶⁴Cu-labeled PSMA-targeting ligand DKFZ-PSMA-617 [95], ⁶⁸Ga-labeled MG7 antibody [96], ⁶⁴Cu/¹⁷⁷Lu-labeled anti-CDH17 nanobody [10, 97], ⁶⁸Ga/¹⁷⁷Lu-labeled anti-CD47 nanobody C2 [98], and LNC1013 (a novel FAPI dimer) [99], ⁹⁰Zr-labeled anti-human DR5 monoclonal antibody CTB006 [100], and ¹²⁴I-labeled trastuzumab and TREM2 probes [101, 102]. With the continuous advancement of research, numerous novel targeted molecular probes for GC have demonstrated promising results in animal models or preclinical trials, thereby advancing non-invasive detection and dynamic assessment of GC.

2.4 Multimodal Fusion Imaging

The combination of functional and anatomical imaging enhances diagnostic reliability. Dual-tracer approaches, such as fusion imaging with ⁶⁸Ga-FAPI-04 and ¹⁸F-FDG dual-tracer PET/CT, improve the detection rate of distant metastases. Additionally, researchers are exploring the integration of PET/MRI hybrid systems with MRI's high soft tissue contrast and molecular information to optimize preoperative T staging and assessment of response to neoadjuvant therapy.

Researchers have leveraged the unique features of different tracers to develop dual-tracer fusion imaging. For example, Miao et al. employed dual-tracer PET/CT using ⁶⁸Ga-FAPI-04 and ¹⁸F-FDG for fusion imaging [103]. Although dual-tracer imaging did not outperform ⁶⁸Ga-FAPI-04 in detecting primary lesions and regional lymph node metastases, fusion imaging not only enhanced the sensitivity of detecting distant metastases in GC patients prior to surgery but also holds promise for improving treatment stratification [103]. Multimodal imaging combining CT and MRI better reflects tumor heterogeneity, aiding in the early identification of pathological response to neoadjuvant chemotherapy in locally advanced GC [104, 105]. Additionally, Wen et al. employed a micro-PET/CT system equipped with trastuzumab and a PET/MRI multimodal imaging technique labeled with ⁶⁴Cu or ¹²⁴I to quantitatively assess HER2 expression in a mouse GC model, thereby facilitating dynamic monitoring of monoclonal antibody (mAb) therapeutic efficacy [64]. Although current research remains limited, we believe multimodal fusion imaging technology holds significant potential for the diagnosis and treatment of GC.

Table 1: Radionuclide PET Imaging of Major Targets in GC.

Target	Expression Rate	Prognosis Relevance	Radionuclide Tracer	Publication Year	Publication
			⁶⁴ Cu-NOTA-Trastuzumab	2018	[61]
HER2	12%-20%	+	⁶⁸ Ga-NOTA-MAL-MZHER2	2021	[63]
			⁸⁹ Zr- Trastuzumab	2018	[62]
			⁸⁹ Zr-anti-CLDN18.2 VHH-ABD	2022	[71]

			89Zr-anti-CLDN18.2 VHH-Fc	2022	[71]
CLDN18.2	40%-50%	+	89Zr-anti-CLDN18.2 VHH-Fc	2022	[71]
			89Zr-DFO-TST001	2023	[73]
			¹²⁴ I-18B10	2023	[74]
			177Lu-DOTA-TST001	2024	[77]
			⁶⁸ Ga-NOTA-RTD98	2024	[82]
Trop2	56%	+	⁶⁸ Ga-NOTA-RTD01	2024	[82]
			⁸⁹ Zr-DFO-Trodelyv	20215	[83]
c-MET	5%-10%	+	⁸⁹ Zr-DFO-AMG102	2017	[88]
			⁸⁹ Zr-DFO-Onartuzumab	2020	[89]
SSR	65%	+	⁶⁸ Ga-DOTA-TATE	2022;2023	[91, 92]
PSMA	66%	-	⁶⁴ Cu-DKFZ-PSMA-617	2017	[95]
MG7	94%	+	⁶⁸ Ga-MG7 Antibody	2015	[96]
CDH17	50%-90%	+	⁶⁴ Cu/ ¹⁷⁷ Lu-Anti-CDH17 Nanobody	2020;2025	[10, 97]
CD47	50%	+	⁶⁸ Ga-C2	2023	[98]
			LNC1013	2025	[99]
DR5	16%	-	⁸⁹ Zr-CTB006	2021	[100]
TREM2	30%-60%	+*	¹²⁴ I- Trastuzumab	2020	[101]

+ indicates prognostic relevance, - indicates no prognostic relevance.

*Specifically referring to macrophage expression.

Table 2: Comparison of Alpha Particle Therapy and Auger Electron (AE) Radioimmunotherapy (RIT).

Treatment Methods	Alpha Particle Therapy	Auger Electron Radioimmunotherapy
Fundamental Principles	Emitting alpha particles causes ionizing radiation	Emissions of Auger electrons trigger DNA damage
Particle Type	Helium nucleus (alpha particle)	Auger Electron
LET Value	High LET (~100 keV/μm)	Ultra-high LET (4–26 keV/μm, with locally higher energy deposition)
Range	Short range (50–100 μm, approximately 5–10 cell diameters)	Ultra-short range (<5 μm, single-cell level interaction)
Types of DNA Damage	Double-strand breaks predominate	Double-strand breaks + base damage composite damage
Penetration Depth	Unable to penetrate intact vascular/tissue barriers	Penetrates the blood-brain barrier (electronic cascade effect)
Therapeutic target	Cell membrane/cytoplasmic targeting (antibody-dependent localization)	Nuclear DNA targeting (requires NLS peptide for nuclear localization)
Applicable Lesion Size	Micrometastatic lesions (0.5–2 mm)	Residual cancer cells/submillimeter lesions
Treatment Cycle	Single-dose administration (due to high-energy rapid killing)	Multiple applications required (low penetration necessitates sustained action)
Clinical Advantages	Rapidly clear lesions and effectively target hypoxic cells	Precision targeting of single cells, capable of penetrating physiological barriers
Limitations	The production of radionuclides is challenging and not suitable for large-volume tumors	A verification system is required to prevent uneven dose distribution

Table 3: Radioactive isotopes primarily used for gastric cancer treatment and their TRT

Radionuclide	Half-life	Energy (MeV)	Target	TRT	Development Stage	Publication Year	Publication
β-emitter							
⁶⁴ Cu	12.7h	0.656	HER2	⁶⁴ Cu-Trastuzumab	Preclinical studies	2019	[108]
			EGFR	⁶⁴ Cu-Cetuximab	Preclinical studies	2022	[109]
⁶⁷ Cu	61.9h	0.577	HER2	⁶⁷ Cu-Trastuzumab	Preclinical studies	2025	[110]
¹³¹ I	8.1days	0.606	CLDN18.2	¹³¹ I-HLX58-Der	Preclinical studies	2025	[113]
				¹³¹ I-Zolbetuximab	Preclinical studies	2025	[114]
			E-cadherin	¹⁷⁷ Lu -d9Mab	Preclinical studies	2011	[116]
			CLDN18.2	¹⁷⁷ Lu-DOTA-TST001	Preclinical studies	2024	[77]
¹⁷⁷ Lu	6.7days	0.479	ATPS	¹⁷⁷ Lu-DOTA-ATPS mAb	Preclinical studies	2024	[8]
			CDH17	¹⁷⁷ Lu-VHH-ABD	Preclinical studies	2025	[97]
			FAP	¹⁷⁷ Lu-LNC1013	Phase II Clinical Trial	2025	[99]
α-emitter							
²¹³ Bi	1h	2.6	E-cadherin	²¹³ Bi-d9mAb	Preclinical studies	2005;2007	[120, 121]
²¹² Pb	10.6h	8.78	HER2	²¹² Pb-TCMC-Trastuzumab	Phase I Clinical Trial	2014	[122]
²¹¹ At	7.2h	7.45		²¹¹ At- Trastuzumab	Preclinical studies	2021	[124, 125]
Auger electrons							
¹²⁵ I	59.6days	0.027	CLDN18.2	¹²⁵ I-Zolbetuximab	Preclinical studies	2024	[136]
¹¹¹ In	2.8days	0.24	HER2	¹¹¹ In-Trastuzumab	Preclinical studies	2022	[137]

4. Targeted Radionuclide Therapy (TRT) of GC

With advances in radioimmunotherapy (RIT) technology, an increasing number of radionuclides have been discovered for cancer treatment. Therapeutic radionuclides can be categorized into three types: beta emitters, alpha emitters, and Auger electron emitters (Figure 1). Targeted radionuclide therapy (TRT) involves labeling radionuclides that emit alpha particles, beta

particles, or Auger electrons onto carriers with specific binding capabilities, and attaching specific chelating agents. This approach enhances compound stability while enabling radionuclide bind to specific tumor targets [106]. The energy released by radionuclides can specifically irradiate tumor tissues and produce biological effects, leading to cellular senescence and death within the irradiation field, thereby achieving precise targeted therapy.




Figure 1: Schematic of targeted radionuclide therapy (TRT).

4.1. Beta-Emitting Radionuclide Therapy

Beta nuclides are one of the most commonly used types of radionuclides in TRT for clinical applications. Beta rays can directly act upon cells, inducing single-strand breaks in DNA. Simultaneously, due to the bystander effect and cross-beam effect associated with β rays, the therapeutic efficacy of β nuclide therapy is often quite significant.

Copper primarily functions as a diagnostic radionuclide. However, some studies indicate that copper may also play a role in the treatment of GC [107]. Zaheer et al. [108]. Conducted experiments using ^{64}Cu -labeled trastuzumab co-administered with paclitaxel in a GC nude mouse model [108]. Results indicated that while the presence or absence of ^{64}Cu did not affect the efficacy of TRZ, radionuclide facilitated deep penetration and uniform distribution of mAbs within the tumor microenvironment (TME). This approach reduced drug toxicity and enhanced protection of surrounding normal tissues [108]. Additionally, reports describe the use of ^{64}Cu -labeled cetuximab in combination with vorinostat (a radiosensitizer) for intraperitoneal radioimmunotherapy (ipRIT) in GC [109]. Results demonstrated that intraperitoneal injection of ^{64}Cu -cetuximab achieved higher and faster drug accumulation at peritoneal metastatic sites, significantly prolonging survival in mouse models. This indicates that ^{64}Cu -cetuximab may represent a potential therapeutic approach for treating peritoneal metastases in GC [109]. Pineau et al. conducted a study using ^{67}Cu -labeled trastuzumab for HER2-positive GC treatment. Results demonstrated significant and dose-dependent inhibition of tumor growth without observed toxicity, indicating its potential as a promising therapeutic agent for GC [110].

Antibody-drug conjugates (ADCs) achieve targeted delivery by chemically linking chemotherapy drugs to specific tumor-associated proteins or antigens through binding to designated target molecules [111]. Due to their high specificity, strong selectivity, favorable clinical efficacy, and lower toxicity risk, ADCs have emerged as an innovative therapeutic approach for various cancers [112]. HLX58 (the CLDN18.2-specific antibody) labeled with ^{125}I can be employed for PET imaging of CLDN18.2+ tumors [113]. Liu et al. combined ^{131}I with the cytotoxic drug Deruxtecan (DXd) and targeted HLX58 to synthesize a radiolabeled antibody-drug conjugate (RADC), namely ^{131}I -HLX58-Der [113]. The average tumor volume in the ^{131}I -HLX58-Der treatment group decreased by 12.15-fold, while that in the HLX58-Der monotherapy group decreased by 4.80-fold. Experiments confirmed that the combination of ^{131}I -induced precise internal radiation therapy and Der's cytotoxic effects delivers a dual-pronged attack against GC [113]. Similarly, Wang et al. evaluated the therapeutic response and toxicity of ^{131}I -Zotuximab in CLDN18.2+ GC mice by preparing the radioligand. Results demonstrated that ^{131}I -Zotuximab exhibited significant therapeutic efficacy and low toxicity [114]. Moreover, with increasing doses, CLDN18.2 expression in tumor tissues significantly decreased, indicating substantially enhanced therapeutic

efficacy and survival rates. This further validates the therapeutic potential of ^{131}I -Zotuximab [114].

^{177}Lu is not only used for tumor imaging but also plays a crucial role in tumor therapy. The β particles emitted by ^{177}Lu effectively target tumor tissue while sparing surrounding healthy tissue, making it one of the most promising therapeutic radionuclides. Currently, ^{177}Lu -DOTA-TATE and ^{177}Lu -PSMA-617 have been approved for the treatment of NETs and prostate cancer, respectively [115]. A study evaluated the therapeutic efficacy of ^{177}Lu -labeled d9Mab (a monoclonal antibody targeting the transmembrane glycoprotein E-cadherin) in a GC nude mouse model [116]. Results demonstrated that ^{177}Lu -d9Mab effectively prolonged survival and exhibited significant efficacy in treating GC via intraperitoneal radiolabeled immunotherapy (ipRIT)[116]. Zeng et al. validated the favorable efficacy and low toxicity of ^{177}Lu -DOTA-TST001 in a CLDN18.2+ GC mouse model, suggesting the potential for personalized RNT based on molecular subtyping [77]. Mao et al. constructed ^{177}Lu -VHH-ABD by labeling CDH17 with a nanobody using ^{177}Lu [97]. In a mouse GC model, ^{177}Lu -VHH-ABD demonstrated prolonged circulation times with increased and sustained tumor accumulation, significantly inhibited tumor growth, offering a promising therapeutic approach for CDH17-overexpressing GCs [97]. In addition, Wang et al. demonstrated for the first time the diagnostic and therapeutic efficacy of $^{68}\text{Ga}/^{177}\text{Lu}$ -LNC1013 (a novel FAPI dimer) in GC patients. Results showed that ^{68}Ga -LNC1013 effectively accumulated in FAP+ tumors and demonstrates higher detection rates across multiple lesion types, including primary tumors, liver metastases, and peritoneal metastases. It also exhibits superior uptake and image contrast compared to ^{18}F -FDG in specific lesions [99]. Simultaneously, they compared the therapeutic efficacy of ^{177}Lu -LNC1013 with that of ^{177}Lu -FAPI-46 (a monomeric FAPI analogue), finding that both radiotracers significantly inhibited tumor growth [99]. However, ^{177}Lu -LNC1013 exhibited longer tumor retention time and demonstrated a more pronounced inhibitory effect [99]. In summary, β -rays can directly induce single-strand breaks in cellular DNA due to their potent tissue penetration and radiation range. Furthermore, owing to the presence of cross-radiation and bystander effects, β -emitting radionuclide-targeted drugs can irradiate neighboring cells and enhance therapeutic efficacy. Most antibodies labeled with β -emitting radionuclides have demonstrated favorable antitumor efficacy and low toxicity, offering a highly promising approach for precision treatment and improved prognosis in gastric cancer.

4.2. Targeted Alpha Therapy (TAT)

Alpha particles are high-energy, highly charged particles with a relatively short range (50–100 μm), but they possess high linear energy transfer (LET) (80 $\text{keV}/\mu\text{m}$) [117]. Compared to β particles (0.2 $\text{keV}/\mu\text{m}$, 0.05–12 mm), alpha particles release substantial energy over extremely short distances, causing intense, irreversible localized damage to tumor cell DNA [117].

The characteristics of α particles make them an effective radiation modality for eliminating circulating malignant cells (such as leukemia cells in blood or bone marrow) or small cell clusters (such as disseminated disease and micrometastatic lesions in solid tumors [118]). Targeted α therapy (TAT) leverages the unique properties of α particle to precisely locate and target cancer cells while minimizing cross-irradiation effects on healthy tissues [119].

Reports have indicated that localized low-dose radioimmunotherapy using ^{213}Bi -radiolabeled antibodies targeting mutant E-cadherin significantly prolongs the median survival time of mice with advanced gastric cancer, reduces CEA levels, and effectively inhibits peritoneal metastasis of GC [120, 121]. It has also been reported that ^{212}Pb can be used in the treatment of HER2+ tumors patients by radiolabeling trastuzumab [122]. ^{211}At is a potential candidate nuclide for TAT due to its chemical properties being suitable for labeling targeting carriers, and its release of only one α particle per decay, which helps control off-target effects [123]. Kodaira et al. performed TAT on HER2+ GC by labeling trastuzumab with ^{211}At [124]. Within the body, ^{211}At -trastuzumab binds to cancer cells and emits α particles, which repeatedly strike the tumor cells along their trajectory. Through high linear energy transfer (LET) and short range, it efficiently kills tumor cells while minimizing collateral damage [124]. Furthermore, additional reports have further validated the antitumor effects of ^{211}At -trastuzumab in HER2+ liver metastatic GC (LMGC), indicating that the TAT of ^{211}At -trastuzumab holds significant potential in GC treatment [125].

In addition to ^{213}Bi and ^{211}At , numerous other radionuclides are being explored for targeted α particle therapy in GC. Currently, α particles commonly used in cancer treatment include ^{212}Pb , ^{223}Ra , and ^{225}Ac . Although current research on the role of these α particles in GC remains insufficient, these radionuclides have been applied in the treatment of various neoplastic diseases, including prostate cancer [126], pancreatic cancer [127], ovarian cancer [128], breast cancer [129], multiple myeloma [130] and NETs [131]. In the future, TAT based on the aforementioned radionuclides will also continue to advance in the field of GC treatment.

4.3. Auger Electron Radioimmunotherapy (AE-RIT)

Auger electrons (AEs) are low-energy electrons emitted when radionuclides undergo internal conversion or electron capture decay. The LET value for Auger electron emission ranges from 4 to 26 keV/ μm , exceeding that of beta particles. Furthermore, the range of Auger electrons is shorter than that of α particles ($<0.5 \mu\text{m}$) (Table 2). Therefore, Auger electrons can directly target the lesion site without damaging surrounding cells [132]. Compared to α particle therapy, which primarily targets small cell clusters, AE-RIT is more suitable for treating micrometastatic lesions and individual cells [133]. Most research on RNT utilizing Auger electrons has employed ^{111}In and ^{125}I . Since the lethal damage Auger electrons inflict on DNA depends on their proximity to nuclear DNA, nuclear localization sequences (NLS) are often re-

quired to facilitate the transport of substances-such as antibodies labeled with Auger electron-emitting radionuclides-to specific targets within the tumour cell nucleus [133, 134].

Yang et al. [135]. Investigated the effects of different doses of radioactive ^{125}I on the growth of GC in mice. The results indicated that Auger electrons emitted by ^{125}I significantly inhibited GC cell growth and effectively promoted the expression of pro-apoptotic factors such as Bax, caspase-3, and caspase-8 within tumour cells [135]. Wang et al. demonstrated the targeting efficacy and therapeutic effect of ^{125}I -labeled Zolbetuximab against CLDN18.2-overexpressing GC [136]. Additionally, Li et al. [137]. Constructed two types of ^{111}In -trastuzumab-NLS for AE-RIT studies in a GC mouse model by radiolabeling trastuzumab with ^{111}In and modifying it with two NLS peptides of differing lengths [137]. Results indicated that both ^{111}In -trastuzumab-NLS variants transported the radionuclide more efficiently into the cell nucleus and demonstrated superior nuclear uptake and intracellular transport in tumor cells compared to ^{111}In -trastuzumab alone [137].

Auger electron radiotherapy holds promise as a potential precision medicine approach due to its narrow energy deposition range and high linear energy transfer (LET) value. This energy deposition minimizes cytotoxicity to healthy cells [138]. By using NLS to co-localize targeting molecules with cell nuclei, energy deposition can be concentrated near DNA, thereby enhancing the efficacy of AE-RIT [139]. Consequently, AE-RIT proves more effective in treating postoperative residual tumours, circulating tumour cells, or micro metastatic lesions in disseminated cancers (Table 3).

4.4. Combination Therapy Strategy

Targeted radionuclide therapy has demonstrated unique potential in the treatment of GC. Most current research focuses on the combination of radionuclides with monoclonal antibodies (mAbs), aiming to hinder tumor progression through the dual effects of RNT and targeted therapy. In addition, nuclide therapy can be combined with radiation therapy, immunotherapy, and other treatment measures to achieve synergistic effects through dual mechanisms, thereby doubling the therapeutic outcomes.

As previously mentioned, the combination therapy of ^{64}Cu -cetuximab and radiotherapy effectively prolonged the survival in GC mouse models compared to monotherapy with ^{64}Cu -cetuximab [109]. Rao et al. discovered that combining ^{177}Lu -trastuzumab with statins enhances HER2 expression on cell surfaces and increases tumour uptake of radiation from ^{177}Lu -trastuzumab. This significantly improves the therapeutic efficacy of ^{177}Lu -trastuzumab in gastric cancer, thereby achieving the objectives of inhibiting tumor growth and prolonging survival [140]. Furthermore, statins exhibit radioprotective effects, reducing radiation toxicity in GC mice receiving combined statin and RNT, demonstrating considerable clinical potential [140]. Park et al. combined the ^{177}Lu -radiolabeled anti-ATP synthase mAb (^{177}Lu -DOTA-ATPS mAb) with the anti-angiogenic drug sunitinib, synergistically enhancing suni-

tinib's therapeutic efficacy. Experiments demonstrated that the combination of ^{177}Lu -DOTA-ATPS mAb with sunitinib resulted in more pronounced tumour volume regression compared to monotherapy, effectively inhibiting tumour progression [8]. Additionally, reports indicate that the combination therapy strategy of ^{177}Lu -labeled LNC1004 (a radiopharmaceutical targeting FAP) with anti-PD-L1 immunotherapy demonstrates promising efficacy for patients with FAP+ tumours [141]. Meanwhile, Simon et al. demonstrated the feasibility of combining ^{177}Lu -DOTA-TATE with photothermal therapy for treating somatostatin receptor (SSR)-positive tumours [142]. Additionally, reports have explored the potential for combination therapies involving TAT alongside external beam radiation therapy (EBRT), immunotherapy, cytotoxic chemotherapy (CCT), and brachytherapy (BT) [143].

Compared to the systemic toxicity associated with drug therapy, TRT significantly reduces the burden on the patient's body. Combining radiotherapy, immunotherapy, and other treatments with targeted radionuclide therapy enables precise delivery of radionuclide-carrier complexes to target sites via delivery systems. This approach achieves dual benefits: delivering targeted treatment while synergistically enhancing therapeutic efficacy, thereby maximizing results with minimal effort.

5. The Integration of Radionuclides in GC Diagnosis and Treatment

Over the past few decades, radionuclides have made remarkable strides, introducing novel concepts for cancer diagnosis and treatment. And the concept of integrating diagnostic imaging with therapeutic intervention is gaining increasing recognition. Using chelating agents to simultaneously deliver diagnostic and therapeutic radionuclides, PET imaging is combined with RIT. This approach enables tumour treatment while allowing real-time monitoring of treatment response, facilitating timely adjustments to the therapeutic regimen.

Wen et al. evaluated the imaging efficacy and therapeutic effects of Her-PEG-dMNPs-nanoprobes loaded with trastuzumab and labeled with ^{64}Cu and ^{124}I [64]. Zhang et al. developed ^{68}Ga -NO-TA-C2 by using a ^{68}Ga -radiolabeled nanobody C2 targeting CD47 to explore its diagnostic value [98]. Simultaneously, they fused C2 with the albumin-binding domain (ABD) to synthesize ABDC2. ABDC2 was labeled with ^{68}Ga , ^{89}Zr , and ^{177}Lu , respectively, to evaluate the diagnostic and therapeutic value of these radionuclides [98]. Through experiments, they validated the real-time monitoring capability of $^{68}\text{Ga}/^{89}\text{Zr}$ and the antitumor efficacy of ^{177}Lu [98]. Additionally, reports have evaluated the diagnostic and therapeutic capabilities of radionuclides by simultaneously administering LNC1013 with ^{68}Ga and ^{177}Lu [99]. Specifically, ^{68}Ga -LNC1013 demonstrated excellent performance in achieving real-time FAP imaging, while ^{177}Lu exhibited stable and sustained antitumor efficacy in the FAP + GC mouse model [99]. This makes $^{68}\text{Ga}/^{177}\text{Lu}$ -LNC1013 a highly promising diagnostic and therapeutic solution for FAP-targeted imaging and simultaneous treatment [99].

Furthermore, the same radionuclide offers inherent advantages in pharmacokinetics and biosafety. The use of a single radionuclide for both imaging and treatment of GC represents a significant advancement in radionuclide technology. For example, there are reports on the use of ^{64}Cu and ^{67}Cu for research into the diagnosis and treatment of GC [110]. Based on the diagnostic capabilities of ^{64}Cu -trastuzumab PET imaging and the therapeutic effects of ^{67}Cu -trastuzumab, a novel diagnostic-therapeutic dual-purpose radiopharmaceutical has been developed. It has demonstrated promising efficacy in both the diagnosis and treatment of HER2+ GC [110].

In summary, by utilizing radiopharmaceuticals or mAb-conjugated nanoparticle carriers to simultaneously deliver diagnostic and therapeutic radionuclides, it is possible to achieve tumour treatment while performing targeted molecular imaging. Moreover, the real-time imaging capability of diagnostic radionuclides enables dynamic monitoring of treatment efficacy, facilitating timely adjustments to therapeutic regimens and achieving seamless integration of diagnosis and treatment. Simultaneously, targeted PET imaging can guide the delineation of radiotherapy target areas, further clarify irradiation boundaries, and reduce irradiation errors. This approach helps minimize bodily damage and enhances treatment precision.

6. Controversies and Future Horizons

The convergence of nuclear medicine, molecular theory, and related multidisciplinary fields has significantly expanded the strategic boundaries of radionuclide therapy, providing powerful tools for precise early warning and treatment of gastric cancer. With its exceptional biological targeting capability and low toxicity to normal tissues, TRT demonstrates tremendous clinical potential as a systemic therapeutic strategy [144]. However, despite significant progress in relevant basic research, radionuclide diagnostics and therapeutics still face unprecedented challenges on the path to clinical translation. A gap remains between scientific achievements and clinical application that urgently requires bridging.

Firstly, enhancing targeted uptake and reducing therapeutic toxicity are core challenges in clinical translation. In terms of diagnosis, the primary challenge facing radionuclide-labeled imaging agents lies in the nonspecific uptake by non-tumorous lesions. For example, radionuclide-labeled FAPI imaging agents may yield false positives due to uptake in inflammatory conditions such as gastritis, thereby compromising the imaging detection of GC lesions [28, 145]. Therefore, it is necessary to further enhance the affinity between the radionuclide and the targeting ligand to improve lesion uptake. Based on differing levels of radionuclide expression, precise localization of tumour lesions and inflammatory lesions can be achieved. In therapeutic applications, to achieve precise delivery of radionuclides to target sites and minimize biological toxicity, a series of strategies have been implemented, including the development of antibody fragments, recombinant proteins, and pre-targeting approaches. Notably, pre-targeting approaches achieve precise and efficient

targeted delivery by first using unlabeled antibodies to target tumour cells, followed by administering the radionuclide-labeled antibody conjugate to the body [146, 147]. This strategy has been validated in tumour models such as colorectal cancer, breast cancer, and neuroblastoma. Additionally, the “mask-release” technology, which masks the binding sites of targeted antibodies using peptide molecules and relies on protease activation within the tumour microenvironment, has also demonstrated potential for reducing off-target tissue toxicity. Its application in the pharmaceutical field remains in the exploratory stage [148].

Secondly, technological innovation and platform optimization will further drive the advancement of precision diagnostics. With progress in multi-omics, artificial intelligence, and surface analysis technologies (for antibodies and other targeted therapies), the ability to identify biomolecules and signaling pathways associated with GC will undergo a qualitative leap. Therefore, the discovery of novel targets is imminent. Meanwhile, high-affinity carriers play a crucial role in TRT. By leveraging the potent inhibitory properties of mAbs and integrating them with novel carriers such as nanoparticles, we can not only further enhance radionuclide enrichment efficiency but also prolong the *in vivo* half-life of radionuclides and improve penetration. This approach ultimately increases tumor uptake and retention time [149]. As the primary demand for radionuclides has gradually shifted from diagnostic imaging to targeted therapy, α emitters with short range and higher energy deposition are gaining significant attention as highly promising therapeutic radionuclides. Alpha particles such as ^{211}At , ^{212}Pb , and ^{225}Ac have been evaluated in patients with various cancers and have demonstrated potent anticancer effects in clinical trials [150, 151]. Currently, most alpha-emitting radionuclides used for therapeutic purposes remain in the preclinical stage. $^{233}\text{Ra-Cl}_2$ is the only alpha-emitting radiopharmaceutical currently approved [152]. For α particles, high production costs and low output remain insurmountable challenges. Currently, high-energy proton irradiation of ^{223}Th can be used to produce large quantities of ^{225}Ac , but the ^{225}Ac extracted through this method remains suboptimal and insufficient to meet widespread therapeutic demands [153]. Recent reports explore the potential for mass-producing α particles using proton accelerators or photoneutron reactions, aiming to reduce production costs while increasing yield [154]. Thirdly, combining TRT with immunotherapy and other approaches to enhance efficacy through sound mechanisms will also be a key area of future research. Numerous reports have demonstrated the use of diagnostic radionuclides such as ^{64}Cu and ^{68}Ga alongside therapeutic radionuclides like ^{131}I and ^{177}Lu to achieve simultaneous diagnosis and treatment of GC [99]. Meanwhile, there are also reports exploring the possibility of using different isotopes of the same element for diagnostic and therapeutic purposes [110]. In the future, the integration of diagnostic and therapeutic applications of radionuclides will be

further advanced [155, 156].

Finally, drug safety, dosimetry, and supply chain management form the foundation for ensuring clinical application. Quality control and safety are paramount, particularly when selecting metal chelators (such as DOTA chelators), where a balance must be struck between labeling efficiency and the drug's lipophilicity and charge characteristics [157]. To address carrier stability damage caused by recoil effects from α -nucleus decay [126, 158], employing carrier molecules with higher affinity and faster internalization rates [159], or encapsulating nuclides within nanoparticles and liposomes, can mitigate damage to healthy organs from free nuclides [160]. At the same time, individualized dosing (dose titration) should not be overlooked [161]. Treatment plans should be tailored to each patient based on the distribution and structure of metastatic lesions. Compared to single-dose administration, fractionated dosing allows for an increased total dose while providing recovery time between doses, thereby helping to reduce systemic toxicity and improve clinical efficacy [147]. Furthermore, given the rapid decay and stringent regulatory requirements of therapeutic radionuclides, establishing globally coordinated regulatory standards, refining the entire supply chain encompassing production, containment, sealed assembly, transportation, and clinical delivery, and developing GMP-compliant large-scale production strategies are essential steps for achieving the key clinical translation of radionuclides [162, 163].

In summary, the integration of radionuclide diagnosis and therapy offers a novel perspective and approach for the early diagnosis of gastric cancer, the removal of micrometastases, and precision treatment. TRT achieves precise targeting by combining radionuclides with carrier molecules, effectively destroying tumours while protecting surrounding healthy tissues. Despite the challenges that persist, ongoing technological advancements and in-depth research will drive further breakthroughs in radionuclide diagnosis and therapy, accelerating its clinical translation. Future progress in radionuclide diagnosis and therapy for gastric cancer requires sustained efforts and research to expedite its clinical application.

7. Funding Statement

This work was funded by the Clinical Research Special Fund of Wu Jieping Medical Foundation (No. 320.6750.2023-19-7), the Open Research Fund of Hubei Province Key Laboratory of Precision Radiation Oncology (No. 2014ZLJZFL014), the National Natural Science Foundation of China (No. 81872429; No. 82473454), the Chinese Society of Clinical Oncology Research Foundation (No. Y-tongshu2021/ms-0107), the Beijing Bethune Public Welfare Foundation (No. BJ-GYQZHX2021006), and the Hubei Xiaoping Chen Science and Technology Development Foundation Jingrui Development Fund (No. CX-PJJH122006-1003).

References

1. Yang W-J, Zhao H-P, Yu Y, Wang J-H, Guo L, Liu J-Y. Updates on global epidemiology, risk and prognostic factors of gastric cancer. *World J Gastroenterol*. 2023; 29(16): 2452-2468.
2. Sundar R, Nakayama I, Markar SR, Shitara K, van Laarhoven HWM. Gastric cancer. *Lancet*. 2025; 405(10494): 2087-2102.
3. Yun M. Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT. *J Gastric Cancer*. 2014; 14(1): 1-6.
4. Kitajima K, Nakajo M, Kaida H, Minamimoto R, Hirata K. Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: an update. *Nagoya J Med Sci*. 2017; 79(4): 527-543.
5. Guan W-L, He Y and Xu R-H. Gastric cancer treatment: recent progress and future perspectives. *J Hematol Oncol*. 2023; 16(1): 57.
6. Luo D, Liu Y, Lu Z and Huang L. Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives. *Mol Med*. 2025; 31(1): 52.
7. Costa IM, Cheng J, Osytek KM, Imberti C and Terry SYA. Methods and techniques for in vitro subcellular localization of radiopharmaceuticals and radionuclides. *Nucl Med Biol*. 2021; 98-99: 18-29.
8. Park B-N, An Y-S, Kim S-M, Lee S-J, Park Y-J. 177Lu Anti-Angiogenic Radioimmunotherapy Targeting ATP Synthase in Gastric Cancer Model. *Antibodies (Basel)*. 2024; 13(3).
9. Qin C, Shao F, Gai Y, Liu Q, Ruan W. 68Ga-DOTA-FAPI-04 PET/MR in the Evaluation of Gastric Carcinomas: Comparison with 18F-FDG PET/CT. *J Nucl Med*. 2022; 63(1): 81-88.
10. Fujiwara K, Akiba H, Tsuji AB, Sudo H, Sugyo A. 64Cu-labeled minibody D2101 visualizes CDH17-positive gastric cancer xenografts with short waiting time. *Nucl Med Commun*. 2020; 41(7): 688-695.
11. Ruder S, Ricaurte-Fajardo A, Sun M. Huicochea Castellanos S. Advances in PSMA-Targeted Radionuclide Therapeutics. *Curr Treat Options Oncol*. 2025; 26(4): 291-301.
12. Jadvar H. Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. *AJR Am J Roentgenol*. 2017; 209(2): 277-288.
13. El Fakiri M, Ayada N, Müller M, Hvass L. Development and Pre-clinical Evaluation of [211At] PSA α -3-Ga: An Inhibitor for Targeted α -Therapy of Prostate Cancer. *J Nucl Med*. 2024; 65(4): 593-599.
14. Leboulleux S, Do Cao C, Zerdoud S, Attard M, Bournaud C. A Phase II Redifferentiation Trial with Dabrafenib-Trametinib and 131I in Metastatic Radioactive Iodine Refractory BRAF p.V600E-Mutated Differentiated Thyroid Cancer. *Clin Cancer Res*. 2023; 29(13): 2401-2409.
15. Dai Q, Liu Y, Ding F, Guo R, Cheng G. CircRNAs: A promising target for intervention regarding glycolysis in gastric cancer. *Heliyon*. 2024; 10(14): e34658.
16. Altini C, Niccoli Asabella A, Di Palo A, Fanelli M, Ferrari C. 18F-FDG PET/CT role in staging of gastric carcinomas: comparison with conventional contrast enhancement computed tomography. *Medicine (Baltimore)*. 2015; 94(20): e864.
17. Dondi F, Albano D, Giubbini R and Bertagna F. 18F-FDG PET and PET/CT for the evaluation of gastric signet ring cell carcinoma: a systematic review. *Nucl Med Commun*. 2021; 42(12): 1293-1300.
18. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. *Nat Med*. 1998; 4(11): 1334-1336.
19. Herrmann K, Ott K, Buck AK, Lordick F, Wilhelm D. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis. *J Nucl Med*. 2007; 48(12): 1945-1950.
20. Staniuk T, Małkowski B, Śrutek E, Szlęzak P and Zegarski W. Comparison of FLT-PET/CT and CECT in gastric cancer diagnosis. *Abdom Radiol (NY)*. 2016; 41(7): 1349-1356.
21. Ott K, Herrmann K, Schuster T, Langer R, Becker K. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. *Ann Surg Oncol*. 2011; 18(12): 3316-3323.
22. Kameyama R, Yamamoto Y, Izuishi K, Takebayashi R, Hagiike M. Detection of gastric cancer using 18F-FLT PET: comparison with 18F-FDG PET. *Eur J Nucl Med Mol Imaging*. 2009; 36(3): 382-388.
23. Honma Y, Terauchi T, Tateishi U, Kano D, Nagashima K. Imaging peritoneal metastasis of gastric cancer with 18F-fluorothymidine positron emission tomography/computed tomography: a proof-of-concept study. *Br J Radiol*. 2018; 91(1089): 20180259.
24. Chen X and Song E. Turning foes to friends: targeting cancer-associated fibroblasts. *Nat Rev Drug Discov*. 2019; 18(2).
25. Kratochwil C, Flechsig P, Lindner T, Abderrahim L. 68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. *J Nucl Med*. 2019; 60(6): 801-805.
26. Ruan D, Zhao L, Cai J, Xu W, Sun L. Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis. *Theranostics*. 2023; 13(13): 4694-4710.
27. Loktev A, Lindner T, Mier W, Debus J, Altmann A. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. *J Nucl Med*. 2018; 59(9): 1423-1429.
28. Gilardi L, Airò Farulla LS, Demirci E, Clerici I. Imaging Cancer-Associated Fibroblasts (CAFs) with FAPI PET. *Biomedicines*. 2022; 10(3).
29. Mona CE, Benz MR, Hikmat F, Grogan TR, Lueckerath K. Correlation of 68Ga-FAPI-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study. *J Nucl Med*. 2022; 63(7): 1021-1026.
30. Arçay Öztürk A and Flamen P. FAP-targeted PET imaging in gastrointestinal malignancies: a comprehensive review. *Cancer Imaging*. 2023; 23(1): 79.
31. Fan C, Guo W, Su G, Chen B and Chen H. Widespread Metastatic Gastric Signet-Ring Cell Carcinoma Shown by 68Ga-FAPI PET/CT. *Clin Nucl Med*. 2021; 46(2): e78-e79.
32. Beyhan E, Çermik TF, Erol Fenercioğlu Ö. The Contribution of 68Ga-FAPI-04 PET/CT to Staging and Prognosis in Gastric Cancer. *Clin Nucl Med*. 2024; 49(10): e485-e491.
33. Lin R, Lin Z, Chen Z, Zheng S, Zhang J. [68Ga] Ga-DOTA-FA-

- PI-04 PET/CT in the evaluation of gastric cancer: comparison with [18F] FDG PET/CT. *Eur J Nucl Med Mol Imaging*. 2022; 49(8): 2960-2971.
34. Zhao Y, Wang S, Du B, Cui Y, Wang Y, Wang Y. Head-to-head Comparison of [68Ga]Ga-FAPI-04 PET and [18F]FDG PET in the Evaluation of Primary Gastrointestinal Tumours and Metastases: A Systematic Review and Meta-analysis. *Academic Radiology*. 2025.
35. Chen H, Pang Y, Li J, Kang F, Xu W, Meng T. Comparison of [68Ga]Ga-FAPI and [18F]FDG uptake in patients with gastric signet-ring-cell carcinoma: a multicentre retrospective study. *Eur Radiol*. 2023; 33(2): 1329-1341.
36. Miao Y, Feng R, Yu T, Guo R, Zhang M. Value of 68Ga-FAPI-04 and 18F-FDG PET/CT in Early Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer. *J Nucl Med*. 2024; 65(2): 213-220.
37. Jiang D, Chen X, You Z, Wang H, Zhang X. Comparison of [68 Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. *Eur J Nucl Med Mol Imaging*. 2022; 49(2): 732-742.
38. Zhang S, Wang W, Xu T, Ding H, Li Y, Liu H. Comparison of Diagnostic Efficacy of [68Ga] Ga-FAPI-04 and [18F]FDG PET/CT for Staging and Restaging of Gastric Cancer. *Front Oncol*. 2022; 12: 925100.
39. Lv J, Zheng K, Jiang C, Yang J, Peng X, Ye H. Evaluating the diagnostic performance of [18F]ALF-NOTA-FAPI-04 PET/CT in gastric cancer: a comparative study with [18F]FDG PET/CT. *Eur Radiol*. 2025; 35(6): 3314-3323.
40. Qin C, Fu Y, Zhang X, Li M, Ruan W, Gai Y. Prognostic value of [68Ga] Ga-FAPI-04 PET in patients with newly diagnosed gastric carcinoma. *Eur J Nucl Med Mol Imaging*. 2025; 52(9): 3075-3086.
41. Rizzo A, Racca M, Garrou F, Fenocchio E, Pellegrino L. Diagnostic Performance of Positron Emission Tomography with Fibroblast-Activating Protein Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis. *Int J Mol Sci*. 2023; 24(12).
42. Huang Y, Cao J, Peng D, Liu H and Chen Y. Bone Marrow Metastases from Gastric Adenocarcinoma on 68Ga-FAPI-04 PET/CT. *Clin Nucl Med*. 2022; 47(2): 151-153.
43. Kuten J, Levine C, Shamni O, Pelles S, Wolf I, Lahat G. Head-to-head comparison of [68Ga] Ga-FAPI-04 and [18F]-FDG PET/CT in evaluating the extent of disease in gastric adenocarcinoma. *Eur J Nucl Med Mol Imaging*. 2022; 49(2): 743-750.
44. Saxena P, Gambhir S and Dixit M. Insight into Tumor Hypoxia: Radionuclide-based Biomarker as Diagnostic Tools. *Curr Top Med Chem*. 2023; 23(12): 1136-1154.
45. Gouel P, Decazes P, Vera P, Gardin I, Thureau S and Bohn P. Advances in PET and MRI imaging of tumor hypoxia. *Front Med (Lausanne)*. 2023; 10: 1055062.
46. Grierson JR, Link JM, Mathis CA, Rasey JS. A radiosynthesis of fluorine-18 fluoromisonidazole. *J Nucl Med*. 1989; 30(3): 343-350.
47. Postema EJ, McEwan AJB, Riauka TA, Kumar P, Richmond DA. Initial results of hypoxia imaging using 1-alpha-D: -(5-deoxy-5-[18F]-fluoroarabino-furanosyl)-2-nitroimidazole (18F-FAZA). *Eur J Nucl Med Mol Imaging*. 2009; 36(10): 1565-1573.
48. Grönroos T, Eskola O, Lehtiö K, Minn H, Marjamäki P. Pharmacokinetics of [18F] FETNIM: a potential marker for PET. *J Nucl Med*. 2001; 42(9): 1397-1404.
49. Barthel H, Wilson H, Collingridge DR, Brown G, Osman S. In vivo evaluation of [18F] fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. *Br J Cancer*. 2004; 90(11): 2232-2242.
50. Wack LJ, Mönnich D, van Elmpt W, Zegers CML, Troost EGC. Comparison of [18F]-FMISO, [18F]-FAZA and [18F]-HX4 for PET imaging of hypoxia--a simulation study. *Acta Oncol*. 2015; 54(9): 1370-1377.
51. Dolbier WR, Li AR, Koch CJ, Shiue CY and Kachur AV. [18F]-EF5, a marker for PET detection of hypoxia: synthesis of precursor and a new fluorination procedure. *Appl Radiat Isot*. 2001; 54(1): 73-80.
52. Nario AP, Woodfield J, Dos Santos SN, Bergman C, Wuest M. Synthesis of a 2-nitroimidazole derivative N-(4-[18F]fluorobenzyl)-2-(2-nitro-1H-imidazol-1-yl)-acetamide ([18 F]FNBNA) as PET radiotracer for imaging tumor hypoxia. *EJNMMI Radiopharm Chem*. 2022; 7(1): 13.
53. Hansen AE, Kristensen AT, Jørgensen JT, McEvoy FJ, Busk M. (64) Cu-ATSM and (18)FDG PET uptake and (64)Cu-ATSM autoradiography in spontaneous canine tumors: comparison with pimonidazole hypoxia immunohistochemistry. *Radiat Oncol*. 2012; 7: 89.
54. Lin W, Huang C, Tan Z, Xu H, Wei W and Wang L. CuII-bis(thioureido) Complex: A Potential Radiotracer for Detecting Oxidative Stress and Neuroinflammation in Neurodegenerative Diseases. *Semin Nucl Med*. 2025; 55(4): 577-586.
55. Colombié M, Gouard S, Frindel M, Vidal A, Chérel M. Focus on the Controversial Aspects of (64) Cu-ATSM in Tumoral Hypoxia Mapping by PET Imaging. *Front Med (Lausanne)*. 2015; 2: 58.
56. Liu T, Dahle MA, Lystad MH, Marignol L, Karlsen M and Redalen KR. In vitro and in vivo characterization of [64Cu] [Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors. *Eur J Nucl Med Mol Imaging*. 2023; 50(12): 3576-3588.
57. Fan L, Chong X, Zhao M, Jia F, Wang Z. Ultrasensitive Gastric Cancer Circulating Tumor Cellular CLDN18.2 RNA Detection Based on a Molecular Beacon. *Anal Chem*. 2021; 93(2): 665-670.
58. Mathenge EG, Dean CA, Clements D, Vaghar-Kashani A, Photopoulos S. Core needle biopsy of breast cancer tumors increases distant metastases in a mouse model. *Neoplasia*. 2014; 16(11): 950-960.
59. Pous A, Notario L, Hierro C, Layos L and Bugés C. HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies. *Int J Mol Sci*. 2023; 24(14).
60. Shitara K, Bang Y-J, Iwasa S, Sugimoto N, Ryu M-H. Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial. *Nat Med*. 2024; 30(7): 1933-1942.
61. Guo X, Zhu H, Zhou N, Chen Z, Liu T, Liu F. Noninvasive Detection of HER2 Expression in Gastric Cancer by 64Cu-NOTA-Trastuzumab in PDX Mouse Model and in Patients. *Mol Pharm*. 2018; 15(11): 5174-5182.

62. O'Donoghue JA, Lewis JS, Pandit-Taskar N. Pharmacokinetics, Biodistribution, and Radiation Dosimetry for ⁸⁹Zr-Trastuzumab in Patients with Esophagogastric Cancer. *J Nucl Med*. 2018; 59(1): 161-166.
63. Zhou N, Liu C, Guo X, Xu Y, Gong J, Qi C. Impact of ⁶⁸Ga-NOTA-MAL-MZHER2 PET imaging in advanced gastric cancer patients and therapeutic response monitoring. *Eur J Nucl Med Mol Imaging*. 2021; 48(1): 161-175.
64. Wen L, Xia L, Guo X, Huang H-F, Wang F. Multimodal Imaging Technology Effectively Monitors HER2 Expression in Tumors Using Trastuzumab-Coupled Organic Nanoparticles in Patient-Derived Xenograft Mice Models. *Front Oncol*. 2021; 11: 778728.
65. Hernandez MC, Yazaki P, Mortimer JE, Yamauchi D. Pilot study of HER2 targeted ⁶⁴Cu-DOTA-tagged PET imaging in gastric cancer patients. *Nucl Med Commun*. 2023; 44(12): 1151-1155.
66. Zhou N, Guo X, Yang M, Zhu H and Yang Z. ⁶⁸Ga-ZHER2 PET/CT Reveals HER2-Positive Metastatic Gastric Cancer with Better Image Quality Than ¹⁸F-FDG. *Clin Nucl Med*. 2020; 45(2): e101-e102.
67. Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD. Monitoring afatinib treatment in HER2-positive gastric cancer with ¹⁸F-FDG and ⁸⁹Zr-trastuzumab PET. *J Nucl Med*. 2013; 54(6): 936-943.
68. Sahin U, Koslowski M, Dhaene K, Usener D, Brandenburg G. Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development. *Clin Cancer Res*. 2008; 14(23): 7624-7634.
69. Inamoto R, Takahashi N and Yamada Y. Claudin18.2 in Advanced Gastric Cancer. *Cancers (Basel)*. 2023; 15(24).
70. Liu S, Zhang Z, Jiang L, Zhang M, Zhang C and Shen L. Claudin-18.2 mediated interaction of gastric Cancer cells and Cancer-associated fibroblasts drives tumor progression. *Cell Commun Signal*. 2024; 22(1): 27.
71. Hu G, Zhu W, Liu Y, Wang Y, Zhang Z, Zhu S. Development and comparison of three ⁸⁹Zr-labeled anti-CLDN18.2 antibodies to noninvasively evaluate CLDN18.2 expression in gastric cancer: a preclinical study. *Eur J Nucl Med Mol Imaging*. 2022; 49(8): 2634-2644.
72. Hu G, Zhu W, Liu Y, Duan W, Zhou P, Li F. strong & gt; Study of ⁸⁹Zr-labeled recombinant antibody VHH-Fc for noninvasive evaluation of CLDN18.2 expression in gastric cancer & lt; strong & gt;. *Journal of Nuclear Medicine*. 2022; 63(supplement 2): 2525.
73. Chen Y, Hou X, Li D, Ding J, Liu J. Development of a CLDN18.2-targeting immuno-PET probe for non-invasive imaging in gastrointestinal tumors. *J Pharm Anal*. 2023; 13(4): 367-375.
74. Wang S, Qi C, Ding J, Li D, Zhang M, Ji C. First-in-human CLDN18.2 functional diagnostic pet imaging of digestive system neoplasms enables whole-body target mapping and lesion detection. *Eur J Nucl Med Mol Imaging*. 2023; 50(9): 2802-2817.
75. Wei W, Zhang D, Zhang Y, Li L, Jin Y, An S. Development and comparison of (⁶⁸Ga/¹⁸F)/(⁶⁴Cu)-labeled nanobody tracers probing Claudin18.2. *Mol Ther Oncolytics*. 2022; 27: 305-314.
76. Wang Z, Zhao C, Ding J, Chen Y, Liu J, Hou X. Screening, Construction, and Preliminary Evaluation of CLDN18.2-Specific Peptides for Noninvasive Molecular Imaging. *ACS Pharmacol Transl Sci*. 2023; 6(12): 1829-1840.
77. Zeng Z, Li L, Tao J, Liu J, Li H, Qian X. [¹⁷⁷Lu] Lu-labeled anti-claudin-18.2 antibody demonstrated radioimmunotherapy potential in gastric cancer mouse xenograft models. *Eur J Nucl Med Mol Imaging*. 2024; 51(5): 1221-1232.
78. Liu X, Li J, Deng J, Zhao J, Zhao G, Zhang T. Targeting Trop2 in solid tumors: a look into structures and novel epitopes. *Front Immunol*. 2023; 14: 1332489.
79. Stein R, Basu A, Chen S, Shih LB and Goldenberg DM. Specificity and properties of MAbs RS7-3G11 and the antigen defined by this pancreatic carcinoma monoclonal antibody. *Int J Cancer*. 1993; 55(6): 938-946.
80. Liu X, Ma L, Li J, Sun L, Yang Y, Liu T. Trop2-targeted therapies in solid tumors: advances and future directions. *Theranostics*. 2024; 14(9): 3674-3692.
81. RETRACTION: The Role and Molecular Mechanism of Trop2 Induced Epithelial-Mesenchymal Transition Through Mediated β -Catenin in Gastric Cancer. *Cancer Med*. 2025; 14(4): e70629.
82. Huang W, Liang C, Zhang Y, Zhang D, An S. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. *Eur J Nucl Med Mol Imaging*. 2024; 51(2): 380-394.
83. Huang W, Li L, Zhou Y, Yang Q, Mixdorf JC, Barnhart TE. Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody-drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer. *Eur J Nucl Med Mol Imaging*. 2025; 52(7): 2369-2383.
84. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmieciak TE. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. *Science*. 1991; 251(4995): 802-804.
85. Van Herpe F and Van Cutsem E. The Role of cMET in Gastric Cancer-A Review of the Literature. *Cancers (Basel)*. 2023; 15(7).
86. Teng L and Lu J. cMET as a potential therapeutic target in gastric cancer (Review). *Int J Mol Med*. 2013; 32(6): 1247-1254.
87. Perk LR, Stigter-van Walsum M, Visser GW, Kloet RW, Vosjan MJ. Quantitative PET imaging of Met-expressing human cancer xenografts with ⁸⁹Zr-labelled monoclonal antibody DN30. *Eur J Nucl Med Mol Imaging*. 2008; 35(10): 1857-1867.
88. Price EW, Carnazza KE, Carlin SD, Cho A, Edwards KJ. (⁸⁹Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection. *J Nucl Med*. 2017; 58(9):1386-1394.
89. Klingler S, Fay R and Holland JP. Light-Induced Radiosynthesis of (⁸⁹Zr-DFO-Azepin-Onartuzumab for Imaging the Hepatocyte Growth Factor Receptor. *J Nucl Med*. 2020; 61(7): 1072-1078.
90. Desai H, Borges-Neto S and Wong TZ. Molecular Imaging and Therapy for Neuroendocrine Tumors. *Curr Treat Options Oncol*. 2019; 20(10): 78.
91. Fabritius MP, Soltani V, Cyran CC, Ricke J, Bartenstein P. Diagnostic accuracy of SSR-PET/CT compared to histopathology in the identification of liver metastases from well-differentiated neuroendocrine tumors. *Cancer Imaging: the Official Publication of the International Cancer Imaging Society*. 2023; 23(1): 92.
92. Ohlendorf F, Henkenberens C, Brunkhorst T, Ross TL, Christiansen H. Volumetric ⁶⁸Ga-DOTA-TATE PET/CT for assessment of

- whole-body tumor burden as a quantitative imaging biomarker in patients with metastatic gastroenteropancreatic neuroendocrine tumors. *Q J Nucl Med*. 2022; 66(4): 361-371.
93. Froelich MF, Schnitzer ML, Holzgreve A, Gassert FG, Gresser E, Overhoff D. Cost-Effectiveness Analysis of ⁶⁸Ga DOTA-TATE PET/CT, ¹¹¹In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors. *Diagnostics (Basel)*. 2021; 11(2).
 94. Ebner R, Rübenthaler J, Ricke J, Sheikh GT, Unterrainer LM. [Imaging of neuroendocrine tumors of the gastrointestinal tract: Value of (hybrid) imaging diagnostics in radiology]. *Radiologie (Heidelb)*. 2024; 64(7): 553-558.
 95. Han X-D, Liu C, Liu F, Xie Q-H, Liu T-L. ⁶⁴Cu-PSMA-617: A novel PSMA-targeted radio-tracer for PET imaging in gastric adenocarcinoma xenografted mice model. *Oncotarget*. 2017; 8(43): 74159-74169.
 96. Xu B, Li X, Yin J, Liang C, Liu L. Evaluation of ⁶⁸Ga-labeled MG7 antibody: a targeted probe for PET/CT imaging of gastric cancer. *Sci Rep*. 2015; 5: 8626.
 97. Mao C, Li S, Fan R, Zhang J, Fan X, Shentu Z. Development and Characterization of the [(177) Lu] Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model. *Mol Pharm*. 2025; 22(4): 2077-2087.
 98. Zhang Y, Zhang D, An S, Liu Q, Liang C. Development and Characterization of Nanobody-Derived CD47 Theranostic Pairs in Solid Tumors. *Research (Wash D C)*. 2023; 6: 0077.
 99. Wang P, Zhang H, Zhao L, Zhang Y, Li F, Su X. Theranostic Potential of [(68)Ga] Ga/[(177)Lu]Lu-LNC1013: A Dual-Purpose Ligand for Cancer Imaging and Radionuclide Therapy. *ACS Appl Mater Interfaces*. 2025.
 100. Wang S, Zhu H, Li Y, Ding J, Wang F. First-in-human DR5 PET reveals insufficient DR5 expression in patients with gastrointestinal cancer. *J Immunother Cancer*. 2021; 9(7).
 101. Guo X, Zhou N, Chen Z, Liu T, Xu X, Lei X. Construction of (124) I-trastuzumab for noninvasive PET imaging of HER2 expression: from patient-derived xenograft models to gastric cancer patients. *Gastric Cancer*. 2020; 23(4): 614-626.
 102. Shi D, Xu Z, Cheng Y, Lin Q, Si Z, Fu W. (124) I-Labeled Immuno-PET Targeting hTREM2 for the Diagnosis of Gastric Carcinoma. *Mol Pharm*. 2023; 20(4): 2235-2244.
 103. Miao Y, Feng R, Guo R, Huang X, Hai W, Li J. Utility of [68Ga] FAPI-04 and [18F] FDG dual-tracer PET/CT in the initial evaluation of gastric cancer. *Eur Radiol*. 2023; 33(6): 4355-4366.
 104. Li J, Zhang H-L, Yin H-K, Zhang H-K, Wang Y. Comparison of MRI and CT-Based Radiomics and Their Combination for Early Identification of Pathological Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer. *J Magn Reson Imaging*. 2023; 58(3): 907-923.
 105. Chen PT and Shih TTF. Editorial for "Comparison of MRI and CT-Based Radiomics and Their Combination for Early Identification of Pathological Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer". *J Magn Reson Imaging*. 2023; 58(3): 924-925.
 106. Allen TM. Ligand-targeted therapeutics in anticancer therapy. *Nat Rev Cancer*. 2002; 2(10): 750-763.
 107. Capriotti G, Piccardo A, Giovannelli E and Signore A. Targeting Copper in Cancer Imaging and Therapy: A New Theragnostic Agent. *J Clin Med*. 2022; 12(1).
 108. Zaheer J, Kim H, Lee YJ, Lim SM and Kim JS. Comparison between Fractionated Dose and Single Dose of Cu-64 Trastuzumab Therapy in the NCI-N87 Gastric Cancer Mouse Model. *Int J Mol Sci*. 2019; 20(19).
 109. Tachibana T, Yoshii Y, Matsumoto H, Zhang M-R, Nagatsu K. Efficacy of vorinostat-sensitized intraperitoneal radioimmunotherapy with ⁶⁴Cu-labeled cetuximab against peritoneal dissemination of gastric cancer in a mouse model. *J Cancer Res Ther*. 2022; 18(4): 907-914.
 110. Pineau J, Ollier C, Mothes C, Belderbos S, Le Bris N and Tripier R. Advanced (⁶⁴Cu/(⁶⁷Cu)-Based Theranostics: Application of the Copper Chelator TE1PA to a Murine Model of HER2-Positive Gastric Cancer. *Inorg Chem*. 2025; 64(24): 12189-12197.
 111. Fu Z, Li S, Han S, Shi C and Zhang Y. Antibody drug conjugate: the "biological missile" for targeted cancer therapy. *Signal Transduct Target Ther*. 2022; 7(1): 93.
 112. McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors. *Clin Cancer Res*. 2023; 29(11): 2131-2143.
 113. Liu Y, Wang X, Zhang N, He S, Zhang J. Utility of ¹³¹I-HLX58-Der for the Precision Treatment: Evaluation of a Preclinical Radio-Antibody-Drug-Conjugate Approach in Mouse Models. *Int J Nanomedicine*. 2025; 20: 723-739.
 114. Wang Y, He S, Ma L, Kuang Z, Mu C, Yang J. Targeted Radionuclide Therapy of CLDN18.2-Positive Gastric Cancer with [¹³¹I] I-Zolbetuximab: An In Vitro and In Vivo Study. *Mol Pharm*. 2025; 22(5): 2535-2544.
 115. Niu T, Fan M, Lin B, Gao F, Tan B and Du X. Current clinical application of lutetium-177 in solid tumors (Review). *Exp Ther Med*. 2024; 27(5): 225.
 116. Seidl C, Zöckler C, Beck R, Quintanilla-Martinez L, Bruchertseifer F and Senekowitsch-Schmidtke R. ¹⁷⁷Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to ²¹³Bi-immunotherapy, but causes toxicity not observed with ²¹³Bi. *Eur J Nucl Med Mol Imaging*. 2011; 38(2): 312-322.
 117. Poty S, Francesconi LC, McDevitt MR, Morris MJ and Lewis JS. α -Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1. *J Nucl Med*. 2018; 59(6): 878-884.
 118. Aghevlian S, Boyle AJ and Reilly RM. Radioimmunotherapy of cancer with high linear energy transfer (LET) radiation delivered by radionuclides emitting α -particles or Auger electrons. *Adv Drug Deliv Rev*. 2017; 109: 102-118.
 119. Bidkar AP, Zerefa L, Yadav S, VanBrocklin HF and Flavell RR. Actinium-225 targeted alpha particle therapy for prostate cancer. *Theranostics*. 2024; 14(7): 2969-2992.

120. Bloechl S, Beck R, Seidl C, Morgenstern A, Schwaiger M and Senekowitsch-Schmidtke R. Fractionated locoregional low-dose radioimmunotherapy improves survival in a mouse model of diffuse-type gastric cancer using a ²¹³Bi-conjugated monoclonal antibody. *Clin Cancer Res*. 2005; 11(19 Pt 2): 7070s-7074s.
121. Beck R, Seidl C, Pfost B, Morgenstern A, Bruchertseifer F. ²¹³Bi-radioimmunotherapy defeats early-stage disseminated gastric cancer in nude mice. *Cancer Sci*. 2007; 98(8): 1215-1222.
122. Meredith R, Torgue J, Shen S, Fisher DR, Banaga E. Dose escalation and dosimetry of first-in-human α radioimmunotherapy with ²¹²Pb-TCMC-trastuzumab. *J Nucl Med*. 2014; 55(10): 1636-1642.
123. Gao J, Li M, Yin J, Liu M, Wang H, Du J. The Different Strategies for the Radiolabeling of [²¹¹At]-Astatinated Radiopharmaceuticals. *Pharmaceutics*. 2024; 16(6).
124. Kodaira S, Li HK, Konishi T, Kitamura H, Kurano M and Hasegawa S. Validating α -particle emission from ²¹¹At-labeled antibodies in single cells for cancer radioimmunotherapy using CR-39 plastic nuclear track detectors. *PLoS One*. 2017; 12(6): e0178472.
125. Li HK, Morokoshi Y, Kodaira S, Kusumoto T. Utility of ²¹¹At-Trastuzumab for the Treatment of Metastatic Gastric Cancer in the Liver: Evaluation of a Preclinical α -Radioimmunotherapy Approach in a Clinically Relevant Mouse Model. *J Nucl Med*. 2021; 62(10): 1468-1474.
126. Bidkar AP, Wang S, Bobba KN, Chan E, Bidlingmaier S. Treatment of Prostate Cancer with CD46-targeted ²²⁵Ac Alpha Particle Radioimmunotherapy. *Clin Cancer Res*. 2023; 29(10): 1916-1928.
127. Bauer D, Carter LM, Atmane MI, De Gregorio R, Michel A. ²¹²Pb-Pretargeted Theranostics for Pancreatic Cancer. *J Nucl Med*. 2024; 65(1): 109-116.
128. Meredith RF, Torgue J, Azure MT, Shen S, Saddekni S, Banaga E, et al. Pharmacokinetics and imaging of ²¹²Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients. *Cancer Biother Radiopharm*. 2014; 29(1): 12-17.
129. Ulaner GA, VanderMolen LA, Li G and Ferreira D. Dotatate PET/CT and ²²⁵Ac-Dotatate Therapy for Somatostatin Receptor-expressing Metastatic Breast Cancer. *Radiology*. 2024; 312(1): e233408.
130. Wadhwa A, Wang S, Patiño-Escobar B, Bidkar AP, Bobba KN. CD46-Targeted Theranostics for PET and ²²⁵Ac-Radiopharmaceutical Therapy of Multiple Myeloma. *Clin Cancer Res*. 2024; 30(5): 1009-1021.
131. Lee D, Li M, Liu D, Baumhover NJ, Sagastume EA, Marks BM, et al. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors. *Eur J Nucl Med Mol Imaging*. 2024; 51(4): 1147-1162.
132. Bolcaen J, Gizawy MA, Terry SYA, Paulo A, Cornelissen B. Marshalling the Potential of Auger Electron Radiopharmaceutical Therapy. *J Nucl Med*. 2023; 64(9): 1344-1351.
133. Ku A, Facca VJ, Cai Z and Reilly RM. Auger electrons for cancer therapy - a review. *EJNMMI Radiopharm Chem*. 2019; 4(1): 27.
134. Elghobary MEN, Munekane M, Mishiro K, Fuchigami T and Ogasawa K. Preparation and Evaluation of Thermosensitive Liposomes Encapsulating I-125-Labeled Doxorubicin Derivatives for Auger Electron Therapy. *Molecules*. 2023; 28(4).
135. Yang Y, Chen A, Ma J, Wu A and Xu F. Effects of radioactive ¹²⁵I on apoptosis of HGC-27 gastric cancer cells. *Oncol Lett*. 2019; 18(5): 4916-4922.
136. Wang Y, Ma L, Kuang Z, Li D, Yang J. Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications. *Mol Pharm*. 2024; 21(8): 3838-3847.
137. Keiko Li H and Hasegawa S. Favorable tumor uptake and nuclear transport of Auger electrons by nuclear targeting with ¹¹¹In-trastuzumab in an intraperitoneal tumor mouse model. *Nucl Med Commun*. 2022; 43(7): 763-769.
138. Suman SK, Balakrishnan B, Mallia MB and Mukherjee A. Tumor-Targeted Radioiodinated Glyconanoparticles for Doxorubicin Delivery and Auger-Chemotherapy in Triple-Negative Breast Cancer. *Small*. 2025; e2502419.
139. Wawrowicz K, Żelechowska-Matysiak K, Majkowska-Pilip A, Wierzbicki M and Bilewicz A. Platinum nanoparticles labelled with iodine-125 for combined "chemo-Auger electron" therapy of hepatocellular carcinoma. *Nanoscale Adv*. 2023; 5(12): 3293-3303.
140. Rao Y, Samuels Z, Carter LM, Monette S, Panikar SS, Pereira PMR, et al. Statins enhance the efficacy of HER2-targeting radioligand therapy in drug-resistant gastric cancers. *Proc Natl Acad Sci U S A*. 2023; 120(14): e2220413120.
141. Zhao L, Pang Y, Zhou Y, Chen J, Fu H. Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade. *Signal Transduction and Targeted Therapy*. 2024; 9(1): 142.
142. Simón M, Jørgensen JT, Khare HA, Christensen C, Nielsen CH and Kjaer A. Combination of [¹⁷⁷Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model. *Pharmaceutics*. 2022; 14(6).
143. Winter RC, Amghar M, Wacker AS, Bakos G, Taş H. Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy. *Pharmaceutics (Basel)*. 2024; 17(8).
144. Constanzo J and Pouget JP. Extracellular vesicles role in radio(nuclide)therapy. *J Radiat Res*. 2024; 65.
145. Pang Y, Zhao L, Luo Z, Hao B, Wu H. Comparison of ⁶⁸Ga-FAPI and ¹⁸F-FDG Uptake in Gastric, Duodenal, and Colorectal Cancers. *Radiology*. 2021; 298(2): 393-402.
146. Altai M, Membreno R, Cook B, Tolmachev V and Zeglis BM. Pre-targeted Imaging and Therapy. *J Nucl Med*. 2017; 58(10): 1553-1559.
147. Lepareur N, Ramée B, Mouglin-Degraef M and Bourgeois M. Clinical Advances and Perspectives in Targeted Radionuclide Therapy. *Pharmaceutics*. 2023;15(6).
148. Cattaruzza F, Nazeer A, To M, Hammond M, Koski C. Precision-activated T-cell engagers targeting HER2 or EGFR and CD3

- mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. *Nat Cancer*. 2023; 4(4): 485-501.
149. Farahavar G, Abolmaali SS, Gholijani N and Nejatollahi F. Antibody-guided nanomedicines as novel breakthrough therapeutic, diagnostic and theranostic tools. *Biomater Sci*. 2019; 7(10): 4000-4016.
150. Bodei L, Herrmann K, Schöder H, Scott AM and Lewis JS. Radiotheranostics in oncology: current challenges and emerging opportunities. *Nat Rev Clin Oncol*. 2022; 19(8): 534-550.
151. Xie L, Zhang L, Hu K, Hanyu M, Zhang Y, Fujinaga M. A ²¹¹At-labelled mGluR1 inhibitor induces cancer senescence to elicit long-lasting anti-tumor efficacy. *Cell Rep Med*. 2023; 4(4): 100960.
152. Zhang S, Wang X, Gao X, Chen X, Li L. Radiopharmaceuticals and their applications in medicine. *Signal Transduction and Targeted Therapy*. 2025; 10(1): 1.
153. Miederer M, Benešová-Schäfer M, Mamat C, Kästner D, Pretze M. Alpha-Emitting Radionuclides: Current Status and Future Perspectives. *Pharmaceuticals (Basel)*. 2024; 17(1).
154. Morgenstern A, Apostolidis C and Bruchertseifer F. Supply and Clinical Application of Actinium-225 and Bismuth-213. *Semin Nucl Med*. 2020; 50(2): 119-123.
155. Kerr CP, Grudzinski JJ, Nguyen TP, Hernandez R, Weichert JP and Morris ZS. Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment. *Pharmaceutics*. 2022; 15(1).
156. Pouget J-P, Chan TA, Galluzzi L and Constanzo J. Radiopharmaceuticals as combinatorial partners for immune checkpoint inhibitors. *Trends Cancer*. 2023; 9(11): 968-981.
157. Crabbé M, Opsomer T, Vermeulen K, Ooms M and Segers C. Targeted radiopharmaceuticals: an underexplored strategy for ovarian cancer. *Theranostics*. 2024; 14(16): 6281-6300.
158. de Kruijff RM, Wolterbeek HT and Denkova AG. A Critical Review of Alpha Radionuclide Therapy-How to Deal with Recoiling Daughters? *Pharmaceuticals (Basel)*. 2015; 8(2): 321-336.
159. Feng Y, Meshaw R, Zhao X-G, Jannetti S, Vaidyanathan G and Zalutsky MR. Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose ²¹¹At-Labeled Anti-HER2 Single-Domain Antibody Fragment. *J Nucl Med*. 2023; 64(1): 124-130.
160. Tallam H, Nair R, Sarkar A, Katugampola S. Preirradiation of Spheroids with ²²⁵Ac-Trastuzumab Improves Penetration of ²²⁵Ac-Liposomes and MIRDcell Predictions of Responses to Drug Cocktails. *J Nucl Med*. 2025; 66(8): 1278-1283.
161. Jang A, Kendi AT, Johnson GB, Halfdanarson TR and Sartor O. Targeted Alpha-Particle Therapy: A Review of Current Trials. *Int J Mol Sci*. 2023; 24(14).
162. Giammarile F, Paez D, Zimmermann R, Cutler CS, Jalilian A. Production and regulatory issues for theranostics. *Lancet Oncol*. 2024; 25(6): e260-e269.
163. Korde A, Mikolajczak R, Kolenc P, Bouziotis P, Westin H. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals. *EJNMMI Radiopharm Chem*. 2022; 7(1): 18.